nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.05.2010 | Review

Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved

verfasst von: Alyse Hopkins, Philip J. Crowe, Jia-Lin Yang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Chemotherapy is administered only to patients with advanced cancers, typically to modest avail. Hence, the search for innovative approaches to treat cancer is growing rapidly. One such approach involves targeting molecular pathways identified as encouraging tumor growth and maintenance, particularly the type 1 insulin-like growth factor (IGF-1) and its receptor (IGF-1R) pathway that is important in conferring chemoresistance.

Materials and Methods

This study focuses on IGF-1R targeted therapy, which will enhance chemotherapy efficacy, through reviewing recent literature from PubMed and Medline databases.

Conclusion

This review examines data and strategies addressing an approach conquering chemoresistance through the combination of IGF-1R targeted therapy and chemotherapy in cancer patients, as well as the mechanisms by which IGF-1R acts as a target. This will impact on future research on treatment selection, thereby improving patient prognosis.

Angelini A, Iezzi M, Di Febbo C, Di Ilio C, Cuccurullo F, Porreca E (2008) Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. Oncol Rep 20:731–735PubMed

Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Therapeutics 315:971–979CrossRef

Atzori F, Tabernero J, Cervantes A, Botero M, Hsu K, Brown H et al (2008) A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. ASCO Meet Abstr 26:3519

Bohula EA, Playford MP, Macaulay VM (2003) Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 14:669–682CrossRefPubMed

Burfeind P, Chernicky C, Rininsland F, Ilan J, Ilan J (1996) Antisense RNA to the type 1 insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 93:7263–7268CrossRefPubMed

Busund L, Ow K, Russell P, Crowe PJ, Yang J (2004) Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. Virchows Arch 444:142–148CrossRefPubMed

Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK et al (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor 1 receptor. Cancer Res 65:3781–3787CrossRefPubMed

Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X (2008) The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 13:3273–3287CrossRefPubMed

Chernicky C, Yi L, Tan H, Gan S, Ilan J (2000) Treatment of human breast cancer cells with antisense RNA to the type 1 insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 7:385–395

Clark MA, Fisher C, Judson IM, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353:701–711CrossRefPubMed

Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A (2007) Ionising radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 26:2423–2434CrossRefPubMed

Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD et al (2005) Delayed activation of the insulin-like growth factor-1 receptro/Src/MAPL/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem 280:14212–14221CrossRefPubMed

Djavan B, Waldert M, Seitz C, Marberger M (2001) Insulin-like growth factors and prostate cancer. World J Urol 19:225–233CrossRefPubMed

Druckman R, Rohr U (2002) IGF-1 in gynaecology and obstetrics. Maturitas 41:S65–S83CrossRef

Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager M, Larsson O (2002) Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Opthalmol Vis Sci 43:1–8

Featherstone C, Jackson SP (1999) Ku, a DNA repair protein with multiple cellular functions? Mutat Res 434:3–15PubMed

Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL et al (2007) American Cancer Society, Atlanta, GA

Ge J, Chen Z, Wu S, Chen J, Li X, Li J et al (2009) Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 80:148–158

Gil-Ad I, Shtaif B, Luria D, Karp L, Fridman Y, Weizman A (1999) Insulin like growth factor 1 (IGF-1R) antagonises apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture. Growth Horm IGF Res 9:458–464CrossRefPubMed

Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131:3109S–3120SPubMed

Girnita L, Girnita A, Prete F, Bartolazzi A, Larrson O, Axelson M (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64:236–242CrossRefPubMed

Gooch JL, Van Den Berg CL, Yee D (1999) Insulin-like growth factor 1 (IGF-1) rescues breast cancer cells from chemotherapy-induced cell death—proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56:1–10CrossRefPubMed

Hakam A, Yeatman T, Lu L, Mora L, Marcet G, Nicosia S et al (1999) Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 30:1128–1133CrossRefPubMed

Haluska P, Shaw H, Batzel GN, Molife LR, Adjei AA, Yap TA et al (2007) Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. ASCO Meet Abstr 25:3586

Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D et al (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13:1198–1207CrossRefPubMed

Hartog H, Wesseling J, Boezen HM, van der Graaf WT (2007) The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 43:1895–1904CrossRefPubMed

Harzstark AL, Ryan C, Diamond M, Jones J, Zavodovskaya M, Maddux B et al (2007) A phase I trial of nordihydroguareacetic acid (NDGA) in patients with non-metastatic prostate cancer and rising PSA. J Clin Oncol 25:15500

Hewish M, Chau I, Cunningham D (2009) Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 4:54–72CrossRefPubMed

Hidalgo M, Tirado Gomez M, Lewis N, Vuky JL, Taylor G, Hayburn JL et al (2008) A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. ASCO Meet Abstr 26:3520

Higano CS, Yu EY, Whiting SH, Gordon MS, LoRusso P, Fox F et al (2007) A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. ASCO Meet Abstr 25:3505

Hochberg Z (2002) Mechanisms of steroid impairment of growth. Horm Res 58:33–38CrossRefPubMed

Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM et al (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69:161–170CrossRefPubMed

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al (2006) Cancer statistics. CA Cancer J Clin 56:106–130CrossRefPubMed

Jiang Y, Rom WN, Yie TA, Chi CX, Tchou-Wong KM (1999) Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-1 receptor. Oncogene 18:6071–6077CrossRefPubMed

Karp DD, Paz-Ares LG, Blakely LJ, Kreisman H, Eisenberg PD, Cohen RB et al (2007) Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ASCO Meet Abstr 25:7506

Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F et al (2009) Phase II study of the efficacy of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. J Clin Oncol 27:2516–2522CrossRefPubMed

Kasper B, Gil T, D’Hondt V, Gebhart M, Awada A (2007) Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol 62:9–15CrossRefPubMed

Korc M (1998) Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 7:25–41PubMed

Kuhn C, Hurwitz SA, Kumar MG, Cotton J, Spandau DF (1999) Activation of the insulin like growth factor-1 receptor promotes the survival o human keratinocytes following ultraviolet B irradiation. Int J Cancer 80:431–438CrossRefPubMed

Lacy M, Alsina M, Melvin CL, Roberts L, Yin D, Petersen A et al (2006) Phase 1 first-in-human dose escalation study of cp-751,871, a specific monoclonal antibody against the insulin like growth factor 1 receptor. J Clin Oncol 24:7609

Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the anti-insulin like growth factor type 1 Receptor monoclonal antibody CP-751, 871 in patients with multiple myeloma. J Clin Oncol 26:3196–3203CrossRefPubMed

Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L et al (2008) Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68:7966–7974CrossRefPubMed

Larrson O, Girnita A, Girnita L (2005) Role of insulin-like growth factor 1 receptor signaling in cancer. Br J Cancer 92:2097–2101CrossRef

Lee C, Wu S, Gabrilovich D, Chen H, Nadaf-Rahrov S, Ciernik I et al (1996) Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 56:3038–3041PubMed

Lee JY, Han CY, Yang JW, Smith C, Kim SK, Lee EY et al (2007) Induction of glutathione transferase in insulin-like growth factor 1 receptor—overexpressed hepatoma cells. Mol Pharmacol 72:1082–1093CrossRefPubMed

Liu X, Turbyville T, Fritz A, Whitesell L (1998a) Inhibition of insulin-like growth factor 1 receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 58:5432–5438PubMed

Liu Y, Lehar S, Corvi C, Payne G, O’Connor R (1998b) Expression of the insulin like growth factor 1 receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells. Cancer Res 58:570–576PubMed

Lloret M, Lara PC, Bordon E, Pinar B, Rev A, Falcon O et al (2007) IGF-1R expression in localised cervical carcinoma patients treated by radiochemotherapy. Gynecol Oncol 106:8–11CrossRefPubMed

Lopez T, Hanahan D (2002) Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1:339–353CrossRefPubMed

Macaulay VM (2004) The IGF receptor as anticancer treatment target. Novartis Found Symp 262:235–243 (discussion 243–246)CrossRefPubMed

Maloney E, McLaughlin J, Dagdigian N, Garrett L, Connors K, Zhou XH et al (2003) An anti-insulin-like growth factor 1 receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073–5083PubMed

Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E et al (2006) A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444:1038–1043CrossRefPubMed

Peters JM, Tsark EC, Wiley LM (1996) Radiosensitive target in the mouse embryo chimera assay: implications that the target involves autocrine growth factor function. Radiat Res 175:722–729CrossRef

Pollak M (2000) Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36:1224–1228CrossRefPubMed

Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R (1994a) Growth inhibition of human melanoma cells in nude mice by antisense strategies to type 1 insulin-like growth factor receptor. Cancer Res 54:4848–4850PubMed

Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R et al (1994b) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1R) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54:2218–2222PubMed

Riedemann J, Sohail M, Macaulay VM, Riedemann J, Sohail M, Macaulay VM (2007) Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells. Biochem Biophys Res Commun 355:700–706CrossRefPubMed

Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM, Rochester MA et al (2005) Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 12:90–100CrossRefPubMed

Rodon J, Patnaik A, Stein M, Tolcher A, Ng C, Dias C (2007) A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. ASCO Meet Abstr 25:3590

Sachdev D, Yee D (2001) The IGF system and breast cancer. Endocr Relat Cancer 8:197–209CrossRefPubMed

Salisbury AJ, Macaulay VM (2003) Development of molecular agents for IGF receptor targeting. Horm Metab Res 35:843–849CrossRefPubMed

Samani A, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47CrossRefPubMed

Sarantopoulos J, Mita AC, Mulay M, Romero O, Lu J, Capilla F et al (2008) A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G). ASCO Meet Abstr 26:3583

Scharf J, Dombrowski F, Ramadori G (2001) The IGF axis and hepatocarcinogenesis. J Clin Pathol 54:138–144CrossRef

Scotlandi K (2006) Targeted therapies in Ewing’s sarcoma. Adv Exp Med Biol 587:13–22PubMed

Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S et al (2005) Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65:3868–3876CrossRefPubMed

Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R (1993) Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90:11217–11221CrossRefPubMed

Surmacz E (2000) Function of the IGF-1 Receptor in breast cancer. J Mammary Gland Biol Neoplasia 5:95–105CrossRefPubMed

Surmacz E (2003) Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor 1 receptor. Oncogene 22:6589–6597CrossRefPubMed

Tanaka S, Arii S (2009) Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 100:1–8CrossRefPubMed

Tolcher AW, Rothenberg ML, Rodon J, Delbeke D, Patnaik A, Nguyen L et al (2007) A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. ASCO Meet Abstr 25:3002

Tolcher AW, Patnaik A, Till E, Takimoto CH, Papadopoulos KP, Massard C et al (2008) A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients (pts) with advanced solid tumor. ASCO Meet Abstr 26:3582

Traxler P (2003) Tyrosine kinases as targets in cancer therapy—successes and failures. Oncol Res 7:215–234

Turner B, Haffty B, Narayanan L, Yuan J, Havre P, Gumbs A et al (1997) Insulin-like growth factor-1 receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57:3079–3083PubMed

Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, Larsson O (2004) The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 23:7854–7862CrossRefPubMed

Von Mehren M (2003) New therapeutic strategies for soft tissue sarcomas. Curr Opin Oncol 4:441–451

Werner H, Le Roith D (2000) New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Proc Natl Acad Sci USA 93:8318–8323CrossRef

Weroha SJ, Haluska P (2008) IGF-1 receptor inhibitors in clinical trials—early lessons. J Mammary Gland Biol Neoplasia 13:471–483CrossRefPubMed

Wunder J, Nielsen T, Maki R, O’Sullivan B, Alman B (2007) Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 8:513–524CrossRefPubMed

Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O (1999) Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 59:3588–3591

Yakar S, LeRoith D, Brodt P (2005) The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16:407–420CrossRefPubMed

Yang JL, Crowe PJ (2007) Targeted therapies in adult soft tissue sarcomas. J Surg Oncol 95:183–184CrossRefPubMed

Zaidi SH, Huddart RA, Harrington KJ (2009) Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol 6:103–134CrossRefPubMed

Titel: Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved
verfasst von: Alyse Hopkins
Philip J. Crowe
Jia-Lin Yang
Publikationsdatum: 01.05.2010
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2010
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0792-0

Neu im Fachgebiet Onkologie

17.04.2024 | Mammakarzinom | Nachrichten

Springer Medizin

Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved

Abstract

Introduction

Materials and Methods

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Update Onkologie

Springer Medizin

Abstract

Introduction

Materials and Methods

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Genetic and protein changes of E-cadherin in meningiomas

TNF superfamily gene polymorphism as prognostic factor in early breast cancer

Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors

Tetrandrine prevents acquired drug resistance of K562 cells through inhibition of mdr1 gene transcription

Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma

Macrophage migration inhibitory factor expression in cervical cancer

Neu im Fachgebiet Onkologie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Update Onkologie